Metformin and Long Non-Coding Rnas in Breast Cancer Publisher Pubmed



Gholami M^{1, 2} ; Klashami ZN¹ ; Ebrahimi P³ ; Mahboobipour AA⁴ ; Farid AS² ; Vahidi A¹ ; Zoughi M² ; Asadi M⁵ ; Amoli MM¹
Source: Journal of Translational Medicine Published:2023

Abstract

Breast cancer (BC) is the second most common cancer and cause of death in women. In recent years many studies investigated the association of long non-coding RNAs (lncRNAs), as novel genetic factors, on BC risk, survival, clinical and pathological features. Recent studies also investigated the roles of metformin treatment as the firstline treatment for type 2 diabetes (T2D) played in lncRNAs expression/regulation or BC incidence, outcome, mortality and survival, separately. This comprehensive study aimed to review lncRNAs associated with BC features and identify metformin-regulated lncRNAs and their mechanisms of action on BC or other types of cancers. Finally, metformin affects BC by regulating five BC-associated lncRNAs including GAS5, HOTAIR, MALAT1, and H19, by several molecular mechanisms have been described in this review. In addition, metformin action on other types of cancers by regulating ten lncRNAs including AC006160.1, Loc100506691, lncRNA-AF085935, SNHG7, HULC, UCA1, H19, MALAT1, AFAP1-AS1, AC026904.1 is described. © 2023, The Author(s).